Skip to main content

Table 2 Distribution of clinical features within genotype groups. Number (N); not applicable (NA); variants that substitute a cysteine for another amino acid (Cys–); missense variants that substitute for a cysteine (Cys+); variants that do not modify cysteine content (Cys-no)

From: Genotype-phenotype spectrum and prognosis of early-onset Marfan syndrome

  

N, (%)

Arachnodactyly

Camptodactyly

Wrist sign

Thumb sign

Pectus deformity

Talipes

Plain pes planus

Hindfoot deformity

Scoliosis/kyphosis

Reduced elbow extension

Senile face appearance

Dolichocephaly

Enophtalmos

Downslanting palpebral fissures

Malar hypoplasia

Micrognatia

Retrognathia

Lens subluxation

Ectopia lentis

Mitral valve regurgitation/prolapse

Aortic root dilation

Diaphragm herniation/relaxation

Cardiac intervention

Outcome (death)

All (%)

 

52 (100)

51 (98)

5 (10)

2 (4)

5 (10)

21 (40)

1 (2)

9 (17)

4 (8)

20 (39)

25 (48)

11 (2)

16 (31)

13 (25)

19 (37)

2 (4)

12 (23)

10 (19)

6 (12)

15 (29)

50 (96)

47 (90)

9 (17)

21 (40)

32 (62)

Haploinsufficiency group

 

8 (15)

8 (100)

2 (25)

0 (0)

0 (0)

3 (37.5)

0 (0)

4 (50)

0 (0)

1 (12.5)

6 (75)

2 (25)

2 (25)

2 (25)

4 (50)

1 (12.5)

0 (0)

1 (12.5)

1 (12.5)

2 (25)

8 (100)

7 (87.5)

1 (12.5)

2 (25)

7 (87.5)

Dominant negative effect group

Cys-

18 (35)

18 (100)

3 (17)

0 (0)

1 (6)

3 (16.7)

0 (0)

2 (11)

1 (6)

7 (39)

8 (44)

4 (22)

7 (39)

2 (11)

8 (44)

0 (0)

5 (28)

4 (22)

2 (11)

5 (28)

18 (100)

16 (89)

3 (17)

7 (39)

11 (61)

Cys+

3 (6)

3 (100)

0 (0)

1 (33)

1 (33)

3 (100)

0 (0)

1 (33)

1 (33)

1 (33)

1 (33)

1 (33)

1 (33)

1 (33)

0 (0)

1 (33)

1 (33)

1 (33)

0 (0)

2 (67)

3 (100)

3 (100)

0 (0)

1 (33)

1 (33)

Cys-no

23 (44)

22 (96)

1 (4)

1 (4)

3 (13)

9 (39)

1 (4)

3 (13)

2 (9)

11 (48)

10 (43.5)

4 (17)

6 (26)

8 (35)

7 (30)

0 (0)

6 (26)

4 (17)

3 (13)

6 (26)

21 (91)

20 (87)

5 (22)

10 (44)

13 (57)